Jump to content

Elipovimab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whoisjohngalt (talk | contribs) at 14:14, 13 January 2020 (Added category). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.[1][2]

References

  1. ^ "GS-9722: FIRST-IN-CLASS EFFECTOR-ENHANCED BROADLY NEUTRALIZING ANTIBODY FOR HIV CURE". CroiConference.Org.
  2. ^ "Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys". Gilead.com.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Elipovimab&oldid=935588410"